View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
November 23, 2018

Deals this week: Roivant Sciences, Inflazome, Santhera

Roivant Sciences will use biologic drug candidate SAL200 are entering a global licensing agreement worth $667.5m with iNtRON Biotechnology.

Roivant Sciences will use biologic drug candidate SAL200 are entering a global licensing agreement worth $667.5m with iNtRON Biotechnology.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

iNtRON will receive payments upon achieving certain developmental, regulatory, and sales-related milestones, as well as royalties on net sales under the agreement.

The deal also provides a licence for iNtRON’s non-clinical stage anti-Gram-positive endolysin programmes, including anti-VRE and anti-TB biologics, for an additional amount of up to $45m for each candidate.

Roivant will also hold the first right of offer for iNtRON’s anti-Gram-negative platform.

Based in the US, Roivant is biopharmaceutical company, while iNtRON is a biotechnology company based in South Korea.

Inflazome has raised €40m ($46m) in a series B financing round led by Forbion.

Longitude Capital also participated in the round, along with the founding investors Novartis Venture Fund and Fountain Healthcare Partners.

“Leo Pharma has entered a $760m partnership with PellePharm to advance the development of novel therapies for rare skin diseases.”

The funds will be used to advance Inflazome’s oral NLRP3 inflammasome inhibitor compounds indicated for inflammatory diseases into clinical trials by 2019.

Based in Ireland, Inflazome is a biopharmaceutical company focussed on the development of treatments for chronic inflammatory conditions.

Santhera has obtained a licence for promising drug candidate vamorolon after entering a partnership with Idorsia.

Santhera will have the option to exclusively in-license the first-in-class dissociative steroid vamorolone by way of sub-license in all indications and countries excluding Japan and South Korea.

Idorsia will receive $20m upfront cash payment and one million new registered shares from Santhera’s existing share capital as part of the deal.

Santhera is a pharmaceutical company, while Idorsia is a biotechnology company. Both are based in Switzerland.

Leo Pharma has entered a $760m partnership with PellePharm to advance the development of novel therapies for rare skin diseases.

Leo has committed $70m in the form of equity financing and research and development (R&D) support for late-stage clinical trial development of patidegib, which is intended for the prevention and treatment of Gorlin Syndrome.

The company also holds the option to acquire PellePharm, for which PellePharm and the stockholders may receive an additional payment of up to $690m.

PellePharm stockholders are also eligible to receive payments for achieving certain developmental and regulatory milestones, as well as double-digit royalties.

Based in Denmark, Leo Pharma is a pharmaceutical company, while PellePharm is an American biotechnology company.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena